Introduction to the Association

Beijing Neurodegenerative Disease Association is a first-level non-profit organization registered with the Beijing Municipal Civil Affairs Bureau and managed by the Beijing Association for Science and Technology. It was established in August 2017 as the Neurodegenerative Disease Committee of the Chinese Society of Microcirculation, which is affiliated with the Chinese Society of Microcirculation, a national professional academic organization founded in November 2013. Currently, both academic bodies share the same management team, led by Professor Li Yanfeng from Peking Union Medical College Hospital. The purpose of the association and committee is to establish an academic exchange platform, promote the development of the national academic level in neurodegenerative diseases, and conduct related academic activities, including grassroots training, research collaboration, and domestic and international academic exchanges.

Scope of Work

The Chinese Society of Microcirculation Neurodegenerative Diseases Committee (CSMNDDC) is a secondary professional association approved by the Chinese Society of Microcirculation, dedicated to academic discussions, technical innovations, clinical practices, and collaboration in the field of neurodegenerative diseases. Its mission is to enhance China's capacity to address and treat neurodegenerative diseases, ultimately serving the health of the people. The Chinese Society of Microcirculation, established in 1993, is a national primary society engaged in microcirculation-related research and academic exchanges. The current chairman is Professor Zhan Qimin, an academician of the Chinese Academy of Engineering and director of the State Key Laboratory of Molecular Oncology at Peking University School of Medicine. The CSMNDDC was successfully established in 2013 under the direct guidance of the society, especially with the care and support of Chairman Zhan Qimin. Professor Li Yanfeng from the Neurology Department of Peking Union Medical College Hospital was elected as the first director of the committee. In line with the medical profession's duty of "using medical skills to help the world and save lives," all members of the committee will contribute their efforts in the clinical prevention and treatment of human neurodegenerative diseases and technological innovations.